Congratulations! BiOptic has won“The 25th Rising Star Award”
2022-11-17
BiOptic has won“The 25th Rising Star Award”, which is awarded by the Ministry of Economic Affairs. We are so honored that BiOptic could stands out from all Bio-industry companies in Taiwan and be the only Bio-company of the 16 winning companies from various industries. The award ceremony was held on the 16th of November, and Dr. Ming-Jhy Hsu, Chief R&D Director, representing BiOptic to receive this award.
Welcome to our booth. This time, you will see the whole Qsep1 series. The world's smallest capillary electrophoresis instrument, including Qsep1-Lite, the entry-level model, Qsep1, the standard model, and Qsep1-Plus, the advanced version.
BiOptic hits a new high in revenue in the first 10-month of 2022
2022-11-11
The world's largest medical tradeshow, MEDICA, in Dusseldorf Germany will be held from November 14th to 17th. BiOptic will participate in the exhibition for the first time after the COVID-19 epidemic. Chairman Eric Tsai said that the company has actively expanded the European market in recent years and the penetration rate continues to increase.
Direct SARS-CoV-2 Detection System Utilizing Simple-to-Use Capillary Gel Electrophoresis
2022-11-08
We present a Direct SARS-CoV-2 Detection System that achieves sample-to-results in less than two hours in three simple steps. The Detection System includes Direct one-step Reverse Transcription PCR (RT-PCR) reagents (Qexp-MDx kit), a portable thermal cycler (Qamp-mini) with a pre-programmed chip, and a simple-to-use Capillary Gel Electrophoresis system (Qsep Series Bio-Fragment Analyzer) with high fluorescence detection sensitivity to solve the problems associated with traditional real-time PCR (qPCR) systems which produce inaccurate test results with high false negative and false positive rates. The proposed simple-to-use detection platform can provide high detection sensitivity (identify less than 20 copies), fast results (less than 120 minutes), and cost-effective results which should be suitable for decentralized testing applications of COVID-19.
